These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37156878)

  • 1. Precision medicine for metastatic TNBC: the FUTURE is now.
    Foldi J; Geyer CE
    Cell Res; 2023 Jul; 33(7):491-492. PubMed ID: 37156878
    [No Abstract]   [Full Text] [Related]  

  • 2. Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?
    Le Du F; Eckhardt BL; Lim B; Litton JK; Moulder S; Meric-Bernstam F; Gonzalez-Angulo AM; Ueno NT
    Oncotarget; 2015 May; 6(15):12890-908. PubMed ID: 25973541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial.
    Jiang YZ; Liu Y; Xiao Y; Hu X; Jiang L; Zuo WJ; Ma D; Ding J; Zhu X; Zou J; Verschraegen C; Stover DG; Kaklamani V; Wang ZH; Shao ZM
    Cell Res; 2021 Feb; 31(2):178-186. PubMed ID: 32719455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The dawn of targeted therapies for triple negative breast cancer (TNBC): a snapshot of investigational drugs in phase I and II trials.
    Huynh MM; Pambid MR; Jayanthan A; Dorr A; Los G; Dunn SE
    Expert Opin Investig Drugs; 2020 Nov; 29(11):1199-1208. PubMed ID: 32869671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multi-omic approach decodes paradoxes of the triple-negative breast cancer: lessons for predictive, preventive and personalised medicine.
    Golubnitschaja O; Filep N; Yeghiazaryan K; Blom HJ; Hofmann-Apitius M; Kuhn W
    Amino Acids; 2018 Apr; 50(3-4):383-395. PubMed ID: 29249020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploitation of Sulfated Glycosaminoglycan Status for Precision Medicine of Triplatin in Triple-Negative Breast Cancer.
    Hampton JD; Peterson EJ; Katner SJ; Turner TH; Alzubi MA; Harrell JC; Dozmorov MG; Turner JBM; Gigliotti PJ; Kraskauskiene V; Shende M; Idowu MO; Puchalapalli M; Hu B; Litovchick L; Katsuta E; Takabe K; Farrell NP; Koblinski JE
    Mol Cancer Ther; 2022 Feb; 21(2):271-281. PubMed ID: 34815360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triple negative aggressive phenotype controlled by miR-135b and miR-365: new theranostics candidates.
    Bertoli G; Cava C; Corsi F; Piccotti F; Martelli C; Ottobrini L; Vaira V; Castiglioni I
    Sci Rep; 2021 Mar; 11(1):6553. PubMed ID: 33753785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subtyping of triple-negative breast cancer: implications for therapy.
    Abramson VG; Lehmann BD; Ballinger TJ; Pietenpol JA
    Cancer; 2015 Jan; 121(1):8-16. PubMed ID: 25043972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A large collection of integrated genomically characterized patient-derived xenografts highlighting the heterogeneity of triple-negative breast cancer.
    Coussy F; de Koning L; Lavigne M; Bernard V; Ouine B; Boulai A; El Botty R; Dahmani A; Montaudon E; Assayag F; Morisset L; Huguet L; Sourd L; Painsec P; Callens C; Chateau-Joubert S; Servely JL; Larcher T; Reyes C; Girard E; Pierron G; Laurent C; Vacher S; Baulande S; Melaabi S; Vincent-Salomon A; Gentien D; Dieras V; Bieche I; Marangoni E
    Int J Cancer; 2019 Oct; 145(7):1902-1912. PubMed ID: 30859564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease.
    Mehlich D; Marusiak AA
    Cancer Lett; 2022 Oct; 547():215775. PubMed ID: 35667515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A bioinformatics approach for precision medicine off-label drug drug selection among triple negative breast cancer patients.
    Cheng L; Schneider BP; Li L
    J Am Med Inform Assoc; 2016 Jul; 23(4):741-9. PubMed ID: 27107440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Personalized treatment in metastatic triple-negative breast cancer: The outlook in 2020.
    Azim HA; Ghosn M; Oualla K; Kassem L
    Breast J; 2020 Jan; 26(1):69-80. PubMed ID: 31872557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triple-negative breast cancer: new treatment strategies in the era of precision medicine.
    Wu SY; Wang H; Shao ZM; Jiang YZ
    Sci China Life Sci; 2021 Mar; 64(3):372-388. PubMed ID: 32803712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PDSS1-Mediated Activation of CAMK2A-STAT3 Signaling Promotes Metastasis in Triple-Negative Breast Cancer.
    Yu TJ; Liu YY; Li XG; Lian B; Lu XX; Jin X; Shao ZM; Hu X; Di GH; Jiang YZ
    Cancer Res; 2021 Nov; 81(21):5491-5505. PubMed ID: 34408002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive metabolomics expands precision medicine for triple-negative breast cancer.
    Xiao Y; Ma D; Yang YS; Yang F; Ding JH; Gong Y; Jiang L; Ge LP; Wu SY; Yu Q; Zhang Q; Bertucci F; Sun Q; Hu X; Li DQ; Shao ZM; Jiang YZ
    Cell Res; 2022 May; 32(5):477-490. PubMed ID: 35105939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing chemotherapy in triple-negative breast cancer: the role of platinum.
    Telli M
    Am Soc Clin Oncol Educ Book; 2014; ():e37-42. PubMed ID: 24857126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated omics-based pathway analyses uncover CYP epoxygenase-associated networks as theranostic targets for metastatic triple negative breast cancer.
    Apaya MK; Shiau JY; Liao GS; Liang YJ; Chen CW; Yang HC; Chu CH; Yu JC; Shyur LF
    J Exp Clin Cancer Res; 2019 May; 38(1):187. PubMed ID: 31072371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer.
    Parsons HA; Beaver JA; Cimino-Mathews A; Ali SM; Axilbund J; Chu D; Connolly RM; Cochran RL; Croessmann S; Clark TA; Gocke CD; Jeter SC; Kennedy MR; Lauring J; Lee J; Lipson D; Miller VA; Otto GA; Rosner GL; Ross JS; Slater S; Stephens PJ; VanDenBerg DA; Wolff AC; Young LE; Zabransky DJ; Zhang Z; Zorzi J; Stearns V; Park BH
    Clin Cancer Res; 2017 Jan; 23(2):379-386. PubMed ID: 27489289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nerve growth factor receptor increases the tumor growth and metastatic potential of triple-negative breast cancer cells.
    Wu R; Li K; Yuan M; Luo KQ
    Oncogene; 2021 Mar; 40(12):2165-2181. PubMed ID: 33627781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Friend or foe: ABCG2, ABCC1 and ABCB1 expression in triple-negative breast cancer.
    Nedeljković M; Tanić N; Prvanović M; Milovanović Z; Tanić N
    Breast Cancer; 2021 May; 28(3):727-736. PubMed ID: 33420675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.